Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of “Hold” by Brokerages

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has been assigned an average rating of “Hold” from the eleven research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $6.34.

Several research analysts have recently issued reports on the stock. UBS Group decreased their price objective on shares of Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating for the company in a report on Friday, March 21st. Bank of America decreased their price target on Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Stifel Nicolaus set a $5.00 price objective on Maravai LifeSciences in a research note on Friday, March 21st. Robert W. Baird cut Maravai LifeSciences from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $9.00 to $3.00 in a research note on Wednesday, February 26th. Finally, Morgan Stanley dropped their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 25th.

Maravai LifeSciences Stock Performance

Shares of MRVI opened at $1.77 on Monday. The firm has a market capitalization of $450.17 million, a PE ratio of -1.08 and a beta of 0.18. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. The firm has a 50-day moving average price of $2.67 and a 200 day moving average price of $4.81. Maravai LifeSciences has a 52-week low of $1.67 and a 52-week high of $11.56.

Insider Activity at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $5.03, for a total transaction of $125,750.00. Following the transaction, the general counsel now directly owns 167,618 shares in the company, valued at $843,118.54. The trade was a 12.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.63% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in shares of Maravai LifeSciences by 1,172.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company’s stock valued at $33,658,000 after buying an additional 3,731,924 shares in the last quarter. Barclays PLC grew its position in Maravai LifeSciences by 349.2% in the third quarter. Barclays PLC now owns 184,189 shares of the company’s stock worth $1,531,000 after acquiring an additional 143,184 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of Maravai LifeSciences during the 4th quarter worth $155,000. Bleakley Financial Group LLC raised its holdings in shares of Maravai LifeSciences by 30.1% during the 4th quarter. Bleakley Financial Group LLC now owns 41,691 shares of the company’s stock valued at $227,000 after purchasing an additional 9,657 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Maravai LifeSciences by 6.3% in the 3rd quarter. Geode Capital Management LLC now owns 2,752,077 shares of the company’s stock valued at $22,874,000 after purchasing an additional 162,601 shares during the last quarter. Hedge funds and other institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.